Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
Crossref DOI link: https://doi.org/10.1007/s10557-018-6792-z
Published Online: 2018-04-27
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bays, Harold E.
Rosenson, Robert S.
Baccara-Dinet, Marie T.
Louie, Michael J.
Thompson, Desmond
Kees Hovingh, G.
Text and Data Mining valid from 2018-04-01
Article History
First Online: 27 April 2018